The UK pharmaceutical industry trade body, the Association of the British Pharmaceutical Industry (ABPI), has welcomed the Prime Minister’s speech on the Government’s negotiating objectives for exiting the EU.
Theresa May’s speech (delivered Tuesday 17 January) set out the 12 negotiating priorities for Brexit as part of the Plan for Britain after leaving the EU.
“Today’s announcement is a welcome statement of intent that provides the UK’s pharmaceutical industry with confidence for the future,” said Mike Thompson, ABPI, Chief Executive.
He added: “The ABPI is pleased that the Prime Minister has identified Britain becoming the best place for science and innovation as one of her twelve negotiation priorities. Our continued leadership in this area will be crucial in creating a truly ‘global Britain’.
“The Prime Minister has also said today that the UK’s new relationship with the EU will be set out by the end of the two-year period following the triggering of Article 50. Throughout this period, we will seek to secure the UK’s continued cooperation and alignment with EU rules for the regulation of medicines. This will be the best possible outcome for UK patients.
“We look forward to continuing to work with Government to make a success of the UK leaving the EU, securing a deal that builds upon our status as a global pharmaceutical industry leader.”
Image credit: Shutterstock.com/ nito